Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials

Bik-Multanowski, 2008, Quality of life in noncompliant adults with phenylketonuria after resumption of the diet, J Inherit Metab Dis, 31, S415, 10.1007/s10545-008-0978-7 Enns, 2010, Suboptimal outcomes in patients with PKU treated early with diet alone: revisiting the evidence, Mol Genet Metab, 101, 99, 10.1016/j.ymgme.2010.05.017 Bilder, 2017, Neuropsychiatric comorbidities in adults with phenylketonuria: a retrospective cohort study, Mol Genet Metab, 121, 1, 10.1016/j.ymgme.2017.03.002 Thomas, 2018, Pegvaliase for the treatment of phenylketonuria: results of a long-term phase 3 clinical trial program (PRISM), Mol Genet Metab, 124, 27, 10.1016/j.ymgme.2018.03.006 Brown, 2016, Phenylketonuria (PKU): A problem solved?, Mol Genet Metab Rep, 6, 8, 10.1016/j.ymgmr.2015.12.004 Vockley, 2014, Phenylalanine hydroxylase deficiency: diagnosis and management guideline, Genet Med, 16, 188, 10.1038/gim.2013.157 Blau, 2015, Alternative therapies to address the unmet medical needs of patients with phenylketonuria, Expert Opin Pharmacother, 16, 791, 10.1517/14656566.2015.1013030 Jurecki, 2017, Adherence to clinic recommendations among patients with phenylketonuria in the United States, Mol Genet Metab, 120, 190, 10.1016/j.ymgme.2017.01.001 Koch, 2002, Phenylketonuria in adulthood: a collaborative study, J Inherit Metab Dis, 25, 333, 10.1023/A:1020158631102 BioMarin Pharmaceutical Inc Pegvaliase (Palynziq): US prescribing information; 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761079s000lbl.pdf (accessed July 10, 2018). Koren, 2008, Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products, J Immunol Methods, 333, 1, 10.1016/j.jim.2008.01.001 Wang, 2014, Immunogenicity and PK/PD evaluation in biotherapeutic drug development: scientific considerations for bioanalytical methods and data analysis, Bioanalysis, 6, 79, 10.4155/bio.13.302 Krishna, 2016, Immunogenicity to biotherapeutics - the role of anti-drug immune complexes, Front Immunol, 7, 21, 10.3389/fimmu.2016.00021 Ponce, 1997, Enzyme therapy in Gaucher disease type 1: effect of neutralizing antibodies to acid beta-glucosidase, Blood, 90, 43, 10.1182/blood.V90.1.43 Chirmule, 2012, Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy, AAPS J, 14, 296, 10.1208/s12248-012-9340-y Verhoef, 2013, Questioning the use of PEGylation for drug delivery, Drug Deliv Transl Res, 3, 499, 10.1007/s13346-013-0176-5 Verhoef, 2014, Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics, Drug Discov Today, 19, 1945, 10.1016/j.drudis.2014.08.015 Hershfield, 2014, Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients, Arthritis Res Ther, 16, R63, 10.1186/ar4500 Wang, 2008, Structural and biochemical characterization of the therapeutic Anabaena variabilis phenylalanine ammonia lyase, J Mol Biol, 380, 623, 10.1016/j.jmb.2008.05.025 Medical Dictionary for Regulatory Activities (MedDRA) Sampson, 2006, Second symposium on the definition and management of anaphylaxis: summary report--second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium, Ann Emerg Med, 47, 373, 10.1016/j.annemergmed.2006.01.018 Brown, 2004, Clinical features and severity grading of anaphylaxis, J Allergy Clin Immunol, 114, 371, 10.1016/j.jaci.2004.04.029 National Cancer Institute Yang, 2016, Analysis of pre-existing IgG and IgM antibodies against polyethylene glycol (PEG) in the general population, Anal Chem, 88, 11804, 10.1021/acs.analchem.6b03437 Chen, 2016, Measurement of pre-existing IgG and IgM antibodies against polyethylene glycol in healthy individuals, Anal Chem, 88, 10661, 10.1021/acs.analchem.6b03109 Nguyen, 2018, Depletion of IgG and IgM before IgE assay indicates pegvaliase-induced hypersensitivity reactions are not IgE-mediated Lubich, 2016, The mystery of antibodies against polyethylene glycol (PEG) - what do we know?, Pharm Res, 33, 2239, 10.1007/s11095-016-1961-x Ishida, 2006, Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes, J Control Release, 112, 15, 10.1016/j.jconrel.2006.01.005 Yang, 2015, Anti-PEG immunity: emergence, characteristics, and unaddressed questions, Wiley Interdiscip Rev Nanomed Nanobiotechnol, 7, 655, 10.1002/wnan.1339